03/16/23 7:30 AMNasdaq : ABUS clinical trialArbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specificRHEA-AIneutral
03/14/23 4:05 PMNasdaq : ABUS Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral ResearchArbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stageRHEA-AIneutral
03/02/23 7:30 AMNasdaq : ABUS earningsArbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate UpdateSignificant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for oral PD-L1, AB-101, and oral RNA Destabilizer, AB-161, expected in the second half of 2023 Initiate PhaseRHEA-AIneutral
02/16/23 7:30 AMNasdaq : ABUS conferencesearningsArbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate UpdateArbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled itsRHEA-AIneutral
02/06/23 7:30 AMNasdaq : ABUS conferencesArbutus to Participate in Three Upcoming Investor ConferencesArbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus managementRHEA-AIneutral
01/27/23 7:30 AMNasdaq : ABUS managementArbutus Announces Resignation of Board MemberArbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Tram Tran, MD hasRHEA-AIneutral
01/05/23 7:30 AMNasdaq : ABUS Arbutus Announces 2023 Corporate Objectives and Provides Financial UpdateData from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in 2023 Strong financial position; cash runway into Q4 2024 WARMINSTER, Pa.,RHEA-AIneutral
12/13/22 7:30 AMNasdaq : ABUS clinical trialArbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus InfectionArbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical companyRHEA-AIneutral
11/09/22 7:30 AMNasdaq : ABUS earningsArbutus Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateFinancially strong with a projected cash runway into the second quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729, our RNAi therapeutic, and NA therapy On-track to achieve multiple additional milestones before yearRHEA-AIneutral
11/08/22 7:30 AMNasdaq : ABUS conferencesArbutus to Present at Jefferies London Healthcare ConferenceArbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arbutus’RHEA-AIneutral